🇺🇸 FDA
Patent

US 9499818

Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene

granted A61KA61K31/56A61K31/57

Quick answer

US patent 9499818 (Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene) held by BIOMARIN TECHNOLOGIES B.V. expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN TECHNOLOGIES B.V.
Grant date
Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/56, A61K31/57, A61K31/573, A61K31/58